Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | NMT2 | O60551 | 5/20 | 0.39 |
| ▸ | NMT1 | P30419 | 5/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75225 | 0.81 | RAB9A (0.47) | RAB9ASMN1; SMN2NPC1MAPTKDM4E | |
| SCHEMBL15016072 | 0.77 | ALDH1A1 (0.40) | RAB9ASMN1; SMN2NPC1MAPTKDM4E | |
| SCHEMBL3612625 | 0.76 | RAB9A (0.68) | RAB9ASMN1; SMN2NPC1MAPTKDM4E | |
| SCHEMBL6836709 | 0.75 | ERN1 (0.45) | SMN1; SMN2ERN1 | |
| SCHEMBL10742515 | 0.75 | RAB9A (0.46) | RAB9ASMN1; SMN2NPC1MAPTKDM4E | |
| SCHEMBL73391 | 0.74 | KDM4E (0.52) | RAB9ASMN1; SMN2NPC1MAPTKDM4E | |
| SCHEMBL5723151 | 0.73 | ALDH1A1 (0.40) | RAB9ASMN1; SMN2MAPTKDM4EL3MBTL1 | |
| SCHEMBL4089689 | 0.72 | ERN1 (0.45) | SMN1; SMN2MAPTERN1 | |
| SCHEMBL9867505 | 0.72 | SMN1; SMN2 (0.50) | RAB9ASMN1; SMN2NPC1MAPTKDM4E | |
| SCHEMBL3607399 | 0.72 | KDM4E (0.76) | RAB9ASMN1; SMN2NPC1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831227-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-06-19 | — | — | EP | claimed |
| US-20090306082-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-12-10 | — | — | US | claimed |
| EP-1831227-A2 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | Glenmark Pharmaceuticals S.A. (CH) | 2007-09-12 | — | — | EP | claimed |
| WO-2006064355-A2 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-06-22 | — | — | WO | claimed |
| EP-1831227-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-8129401-B2 | Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20110190303-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-08-04 | — | — | US | disclosed |
| US-7943634-B2 | Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-05-17 | — | — | US | disclosed |
| US-20090306082-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
| EP-1831227-A2 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | Glenmark Pharmaceuticals S.A. (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006064355-A2 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306082-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PTGER4, NOX4, PDE4A | RAB9A 933/4885SMN1; SMN2 1455/4885NPC1 3745/4885 |
| US-20110190303-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PTGER4, NOX4, PDE4A | RAB9A 1025/4885SMN1; SMN2 1511/4885NPC1 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.